Literature DB >> 26628205

Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm.

Vania Aikawa1, David Porter2, Marlise R Luskin2, Adam Bagg3, Jennifer J D Morrissette3.   

Abstract

Donor cell leukemia is a rare complication of allogeneic hematopoietic stem cell transplantation (HSCT), which may result from the development of a new malignancy in previously healthy donor cells after transplant into the recipient, or it may derive from the transmission of an occult leukemia from donor to recipient. We report a case of donor derived 20q11.2 deletion in a male patient who received an allogeneic HSCT from his HLA-identical sister for the treatment of his chronic lymphocytic leukemia. Bone marrow cells from the donor were found to contain the 20q deletion that expanded over time, but which was absent in her peripheral blood cells. Although cases of donor cell leukemia after HSCT have been reported, in this case there has been no evidence of an associated hematologic neoplasm in either the donor or recipient. Pre-transplant donor bone marrow evaluations are not practical or warranted, however the finding of new cytogenetic abnormalities after transplant mandates a thorough evaluation of the donor.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  20q deletion; Donor cell leukemia; allogeneic hematopoietic stem cell transplantation; chronic lymphocytic leukemia

Mesh:

Year:  2015        PMID: 26628205     DOI: 10.1016/j.cancergen.2015.10.003

Source DB:  PubMed          Journal:  Cancer Genet


  3 in total

1.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.

Authors:  Lindsay M Morton; Wael Saber; K Scott Baker; A John Barrett; Smita Bhatia; Eric A Engels; Shahinaz M Gadalla; David E Kleiner; Steven Pavletic; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-12       Impact factor: 5.742

Review 2.  Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Authors:  Mohamed A Kharfan-Dabaja; Ambuj Kumar; Mehdi Hamadani; Stephan Stilgenbauer; Paolo Ghia; Claudio Anasetti; Peter Dreger; Emili Montserrat; Miguel-Angel Perales; Edwin P Alyea; Farrukh T Awan; Ernesto Ayala; Jacqueline C Barrientos; Jennifer R Brown; Januario E Castro; Richard R Furman; John Gribben; Brian T Hill; Mohamad Mohty; Carol Moreno; Susan O'Brien; Steven Z Pavletic; Javier Pinilla-Ibarz; Nishitha M Reddy; Mohamed Sorror; Christopher Bredeson; Paul Carpenter; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-19       Impact factor: 5.742

3.  Clonal dominance of a donor-derived del(20q) clone after allogeneic hematopoietic stem cell transplantation in an acute myeloid leukemia patient with del(20q).

Authors:  Jung Yoon; Jae Won Yun; Chul Won Jung; Hee-Jin Kim; Sun-Hee Kim
Journal:  J Clin Lab Anal       Date:  2019-06-11       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.